Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMSIACS: Evolocumab Added to Statin Therapy in Acute Coronary Syndrome
NCT04100434Phase 4Unknown
- Sponsor
- Tianjin Chest Hospital
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in acute coronary syndrome (ACS), sponsored by Tianjin Chest Hospital. Status: unknown.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04100434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100434.